Full Text
PCN15 CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH DUKES' C COLON CANCER- PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL– DATA FROM CZECH PERSPECTIVE

Abstract

Authors

L Jiraskova T Dolezal

Back to Volume 9, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×